

9-5-00

Box
Seal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Patent Examining Operations

Applicant(s): Eisinger et al
Serial No: Unassigned Art Unit: Unassigned
Filed: Herewith Examiner: Unassigned
Title: A RECOMBINANT MONOCLONAL ANTIBODY TO
PHOSPHOTYROSINE-CONTAINING PROTEINS
Docket No: 724650-3

JC836 U.S. PTO
09/653755
09/01/00

09/01/00
JC675 U.S. PTO

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Application Transmittal Letter

Sir:

Transmitted herewith for filing is the patent application of:

Dominic Eisinger, Lynn Stiles, Arthur LaMarche and Thomas Jelinek

entitled: A RECOMBINANT MONOCLONAL ANTIBODY TO PHOSPHOTYROSINE-
CONTAINING PROTEINS

Enclosed with the application are:

1. Application (46 sheets), Drawings (5 sheets); Sequence Listing 10 sheets);
2. Declaration of Eisinger et al (unexecuted, 2 sheets);
3. Statement under 37 C.F.R. 1.821(f);
4. Sequence Listing in computer readable form (3.5" diskette);
5. Verified Small Entity Form
6. Postage paid, return receipt postcard; and
7. A check in the amount of \$353.00.

The PTO did not receive the following
listed item(s) Check for \$353.00.
Received Check for \$353.00

09/01/00

The fee has been calculated as follows:

	<u>Number of Claims Filed</u>	<u>Extra Claims</u>	<u>Rate</u>	<u>Fee</u>
Basic Fee			\$345	\$345
Total Claims	32 - 20 = 12	X	\$ 9	\$108
Indep. Claims	3 - 3 = 0		\$ 78	\$ 0
TOTAL:				\$453

The Commissioner is authorized to charge payment of any additional filing fees required under 37 CFR 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

EXPRESS MAIL CERTIFICATE

Express Mail Label No. EL290883550US

Deposit Date: 1 September 2000

I hereby certify that this paper and the attachments hereto are being deposited today with the U.S. Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above addressed to:

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, DC 20231


Alan J. Grant, Esq.

9/1/00
Date

Respectfully submitted,



Alan J. Grant, Esq.
Reg. No. 33,389
CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
6 Becker Farm Road
Roseland, NJ 07068
Tel. No.: (973) 994-1700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Eisinger et al
Serial No: Unassigned Art Unit: Unassigned
Filed: Herewith Examiner: Unassigned
Title: A RECOMBINANT MONOCLONAL ANTIBODY TO
PHOSPHOTYROSINE-CONTAINING PROTEINS
Docket No: 724650-3

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Statement Under 37 CFR 1.821(f)

Sir:

Applicant hereby asserts that the paper Sequence Listing filed herewith and the CRF form (diskette) of the Sequence Listing filed herewith are the same.

Respectfully submitted,



Alan J. Grant
Reg. No. 33,389
CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
6 Becker Farm Road
Roseland, NJ 07068
Tel. No.: (973) 994-1700

001050 " 5345550

VERIFIED STATEMENT(DECLARATION) CLAIMING SMALL ENTITY STATUS

37 CFR 1.9(f) and 1.27(c) - SMALL BUSINESS CONCERN

I hereby declare that I am

☐ the owner of the small business concern identified below:☒ an official of the small business concern empowered to act on behalf of the concern identified below:NAME OF CONCERN: UPSTATE BIOTECHNOLOGYADDRESS OF CONCERN: 199 Saranac Road, Lake Placid, NY 12946

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the number of persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled:

A RECOMBINANT MONOCLONAL ANTIBODY TO PHOSPHOTYROSINE-CONTAINING PROTEINS

inventor: Eisinger et al

described in:

☒ the specification filed herewith☐ application serial no. _____ filed _____☐ patent no. _____ issued _____

If the rights held by the small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or as a nonprofit organization under 37 CFR 1.9(e).

NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME: DOMINIC EISINGERADDRESS: EAST HILL Rd LAKE PLACID NY 12942☐ Individual☒ Small business☐ Nonprofit organization

NAME: _____

ADDRESS: _____

☐ Individual☐ Small business☐ Nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF PERSON SIGNING DOMINIC EISINGERTITLE IN ORGANIZATION R+D LAB MANAGERADDRESS OF PERSON SIGNING EAST HILL Rd LAKE PLACID NY 12942SIGNATURE [Signature] DATE 8-30-00

CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN
6 Becker Farm Road - Roseland, NJ 07068 - (973) 994-1700

Docket No: 724650-3

A RECOMBINANT MONOCLONAL ANTIBODY TO PHOSPHOTYROSINE-CONTAINING PROTEINS

5

FIELD OF THE INVENTION

The present invention relates to the field of recombinant monoclonal antibodies and their uses in clinical and scientific procedures, including diagnostic procedures, especially where such processes involve the detection of phosphotyrosine-containing proteins.

15

BACKGROUND OF THE INVENTION

Cellular growth, especially the uncontrolled growth seen in cancers, has, at least partly, been attributed to the functions of protein kinases that add phosphate to the hydroxyl group of tyrosine. In a similar way, oncogenic transformation of cells by entities such as Rous sarcoma virus and murine leukemia virus, leads to a significant increase, by at least an order of magnitude, in the level of phosphotyrosines seen in both virus-encoded proteins and proteins found in the transformed cells. Tyrosine kinases are believed intimately involved in such transformation processes.

25

Anti-phosphotyrosine monoclonal antibodies specific for proteins containing phosphotyrosine residues have proven valuable in studying such transformation processes, as well as in the detection of phosphotyrosine residues in proteins and detection of proteins containing such moieties.

Thus, because oncogenes present in transforming organisms have been found to have natural counterparts, or homologs, within the untransformed cells, tyrosine-kinases have been implicated in normal growth control, possibly including during embryonic development or regeneration.

5 Consequently, the availability of significant quantities of monoclonal antibodies with specificity directed toward such proteins can be of far reaching value, especially where methods are available for the production of such antibodies on a high scale. For example, monoclonal antibodies can facilitate the identification of cellular substrates for tyrosine kinases and
10 make possible affinity purification of their substrates as well as being highly useful in screening for, and detecting, diseases.

Modern technology, such as that involving the use of hybridomas, has made available to researchers and clinicians alike sources of highly specific
15 and potent monoclonal antibodies useful in general diagnostic and clinical procedures, such as where these antibodies are specific for phosphotyrosine-containing proteins and polypeptides. Among the more useful monoclonal antibodies are those derived from the 4G10 hybridoma cell line. The 4G10 monoclonal antibody is described further in Oda et al, *Blood*, Crkl is
20 constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin, **88**(11):4304-13 (Dec. 1, 1996). However, while such antibodies are useful, they are not easy to produce in pure form. For example, the 4G10 cell line is a low producer of the required antibodies and
25 therefor it is difficult, as well as expensive, to procure such antibodies in sufficient quantity to support all the different uses to which they might be put. In addition, the quality of said antibodies from one lot to another may also be less than what is desired by most researchers and clinicians.

More specifically, the purified His tagged recombinant antibody is purer than what can be obtained from the hybridoma source. The hybridoma Protein A purified 4G10 has an as yet unidentified heavy chain doublet whereas the IMAC purified recombinant antibody of the present invention is highly pure with a single heavy chain band and light chain band. Furthermore, the phosphotyrosine binding properties of 4G10 are sensitive to acid exposure and elution from Protein A or G columns with the required low pH conditions leads to partial inactivation and thus a lower specific activity.

The present invention solves such problems by offering a recombinant monoclonal antibody comprising utility and specificity the same or similar to that derived from the 4G10 hybridoma cell line but showing much greater purity with concomitant high specific activity and consistency of performance. Especially useful is the histidine-tagged form of the immunoglobulin of the present invention. The His tag allows for IMAC (immobilized metal affinity chromatography) purification under neutral pH conditions so that the recombinant antibody is never exposed to low pH conditions. Greater purity is, of course, highly useful in clinical applications.

The His tag is also useful in that it facilitates attachment of the recombinant antibody or immunoglobulin in an orientated fashion to Nickel matrices for solid phase applications. Thus, the His tagged recombinant form is particularly useful. The methods disclosed herein thus afford a purer and more uniform product with generally higher specific activity.

BRIEF SUMMARY OF THE INVENTION

The present invention relates to a recombinant monoclonal antibody having specificity directed to proteins and polypeptides comprising phosphotyrosine moieties.

It is therefore an object of the present invention to provide for a recombinant monoclonal antibody having specificity for phosphotyrosine-containing proteins and polypeptides.

It is a further object of the present invention to provide polynucleotides, such as cDNAs, whose nucleotide sequences code for the heavy and light chains of the aforementioned recombinant antibodies and immunoglobulins.

It is a still further object of the present invention to provide recombinant antibodies specific for phosphotyrosine-containing proteins and polypeptides wherein said antibodies are tagged with sequences of amino acids, and other tags, making them easily isolatable as well as affording versatility in using said antibodies for research, diagnostic and clinical purposes.

It is another object of the present invention to provide a method of using the recombinant antibodies disclosed herein for research, diagnostic and clinical uses.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows an immunoblot of EGF (epidermal growth factor) stimulated A431 cell extracts probed with conditioned media from COS cells transfected with 4G10 hybridoma light chain and heavy chain cDNAs. Lane 1, HC clone-42 and LC clone-14; Lane 2, HC clone-42 and LC clone-11; Lane 3, HC clone-44 and LC clone-14; Lane 4, HC clone-44 and LC clone-11; Lane 5, native 4G10 at 1 μ g/ml. Molecular weight markers in kilodaltons are indicated at the left.

10

Figure 2 shows an immunoblot of EGF stimulated A431 cell extracts probed with conditioned media from COS cells transfected with 4G10 hybridoma light chain and His-tagged heavy chain cDNAs. Lane 1, HC clone-3His and LC clone-11; Lane 2, HC clone-7His and LC clone-11; Lane 3, native 4G10 at 2 μ g/ml; Lane 4, same as Lane 1 except for the addition of 50 mM phenylphosphate to the conditioned media used for primary antibody probing; Lane 5, same as Lane 2 except for the addition of 50 mM phenylphosphate to conditioned media used for primary antibody probing. Molecular weight markers in kilodaltons are indicated at the left.

20

Figure 3 shows an immunoprecipitation immunoblot of EGF stimulated A431 cell extracts. 500 μ g of cell extract was immunoprecipitated (IP) with 4 μ g of recombinant or native 4G10 antibody purified from CHO cells and probed with recombinant or native 4G10 at a concentration of 2 μ g/ml. Lane 1, IP-antibody = r4G10 (recombinant 4G10), no primary antibody; Lane 2, IP-antibody = native 4G10, no primary antibody; Lane 3, IP-antibody = r4G10, primary antibody = r4G10; Lane 4, IP-antibody = native 4G10, primary antibody = r4G10; Lane 5, IP-antibody = r4G10, primary antibody = native 4G10; Lane 6, IP-antibody = native 4G10, primary antibody =

native 4G10. Molecular weight markers in kilodaltons are indicated at the left.

Figure 4 shows an immunoblot of EGF stimulated A431 cell extracts
5 probed with 1 ug/ml purified recombinant 4G10 stored under different
conditions. Lane 1, No primary antibody. Lane 2, Recombinant 4G10 frozen
at -20 °C in 30% glycerol. Lane 3, Recombinant 4G10 stored at 4 °C.
Molecular weight markers in kilodaltons are indicated at the left.

10 Figure 5 shows that His-tagged recombinant 4G10 is purer than native
(commercially available) 4G10 as determined by SDS-PAGE. Lane 1, 6
micrograms of His-tagged r4G10 (r = recombinant); Lane 2, Molecular
weight marker; Lane 3, 6 micrograms of native 4G10. Molecular weight
markers in kilodaltons are indicated at the left.

DETAILED SUMMARY OF THE INVENTION

20 With the advent of methods of molecular biology and recombinant
technology, it is now possible to produce antibody molecules by recombinant
means and thereby generate gene sequences that code for specific amino
acid sequences found in the polypeptide structure of the antibodies. Such
antibodies can be produced by either cloning the gene sequences encoding
25 the polypeptide chains of said antibodies or by direct synthesis of said
polypeptide chains, with *in vitro* assembly of the synthesized chains to form
active tetrameric (H₂L₂) structures with affinity for specific epitopes and
antigenic determinants. This has permitted the ready production of
antibodies having sequences characteristic of neutralizing antibodies from
30 different species and sources.

Regardless of the source of the antibodies, or how they are recombinantly constructed, or how they are synthesized, *in vitro* or *in vivo*, using transgenic animals, such as cows, goats and sheep, using large cell
5 cultures of laboratory or commercial size, in bioreactors or by direct chemical synthesis employing no living organisms at any stage of the process, all antibodies have a similar overall 3 dimensional structure. This structure is often given as H_2L_2 and refers to the fact that antibodies commonly comprise 2 light (L) amino acid chains and 2 heavy (H) amino acid chains. Both chains
10 have regions capable of interacting with a structurally complementary antigenic target. The regions interacting with the target are referred to as "variable" or "V" regions and are characterized by differences in amino acid sequence from antibodies of different antigenic specificity.

15 The variable regions of either H or L chains contains the amino acid sequences capable of specifically binding to antigenic targets. Within these sequences are smaller sequences dubbed "hypervariable" because of their extreme variability between antibodies of differing specificity. Such hypervariable regions are also referred to as "complementarity determining
20 regions" or "CDR" regions. These CDR regions account for the basic specificity of the antibody for a particular antigenic determinant structure.

The CDRs represent non-contiguous stretches of amino acids within the variable regions but, regardless of species, the positional locations of
25 these critical amino acid sequences within the variable heavy and light chain regions have been found to have similar locations within the amino acid sequences of the variable chains. The variable heavy and light chains of all antibodies each have 3 CDR regions, each non-contiguous with the others (termed L1, L2, L3, H1, H2, H3) for the respective light (L) and heavy (H)
30 chains. The accepted CDR regions have been described by Kabat et al, *J.*

Biol. Chem. **252**:6609-6616 (1977). The numbering scheme is shown in the figures, where the CDRs are underlined and the numbers follow the Kabat scheme.

5 In all mammalian species, antibody polypeptides contain constant (i.e., highly conserved) and variable regions, and, within the latter, there are the CDRs and the so-called "framework regions" made up of amino acid sequences within the variable region of the heavy or light chain but outside the CDRs.

10

 In accordance with the foregoing, the present invention is directed generally to a recombinant monoclonal antibody having specificity directed to proteins and polypeptides comprising phosphotyrosine moieties.

15 The present invention further relates to a polypeptide which has the deduced amino acid sequence (SEQ ID NO: 4, 5 or 6), as well as immunologically active fragments, analogs and derivatives of such polypeptide.

20 The terms "fragment," "derivative" and "analog" when referring to a polypeptide (such as SEQ ID NO: 4, 5 or 6), means a fragment, derivative or analog of the polypeptide that retains essentially the same biological function or activity as such polypeptide. Thus, an analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide. Such fragments, derivatives and analogs must have
25 sufficient similarity to the polypeptide of SEQ ID NO: 4, 5 or 6 so that the immunological activity and/specificity of the native polypeptide is retained. In accordance with the present invention, when composing antibodies, such a fragment would include Fab and F(ab')₂ fragments but the invention is in no way limited only to such fragments.

30

09653755-090100

The polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or, in general, a synthetic polypeptide, meaning a polypeptide other than one occurring naturally, preferably a recombinant polypeptide having the immunological specificity and/or activity disclosed herein and including immunologically active fragments thereof. The antibodies formed of the polypeptides of the present invention may likewise be dimeric in nature, consisting of only one heavy and one light chain, or may be chimeric or humanized or other form of recombinant antibody.

10 The immunoglobulins of the present invention include those with amino acid sequences substantially identical to the sequences of SEQ ID NO: 4, 5 or 6. As used herein, the term "substantially identical" includes sequences at least 98% identical to the sequences disclosed herein or sequences wherein (i) one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) which is of the same chemical character as the amino acid being substituted for, such as where a hydrophobic residue is replaced by another hydrophobic residue, or where an acidic residue is replaced by another acidic residue, or where a basic residue is replaced by another basic residue, or where a polar residue is replaced by another polar residue, especially where the respective amino acids are of similar size. Such amino acids may also be replaced by amino acids of similar size and chemical character but which are not amino acids normally coded for by the genetic code or where one or more of the amino acid residues includes a specialized substituent group. The purified, or highly pure, immunoglobulins of the present invention may also be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or where the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature

polypeptide or a proprotein sequence. Such analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

The immunoglobulins of the present invention are preferably provided in
5 an isolated form, and preferably are purified to homogeneity.

Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for
10 producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.

As used herein, the terms "portion," "segment," and "fragment,"
15 when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would represent portions,
20 segments or fragments of the starting polypeptide.

In accordance with the foregoing, the present invention relates to a purified or highly pure immunoglobulin having the same specificity as 4G10 monoclonal antibody (available commercially from Upstate Biotechnology
25 Inc., Lake Placid, NY). This purified immunoglobulin, which term includes antibodies, such as monoclonal antibodies, regardless of how prepared, including by direct chemical synthesis, comprises two light chain components and two heavy chain components wherein said heavy chain components exhibit a single band on gel electrophoresis. The commercially
30 available form heretofore available exhibits a heavy chain doublet and thus

shows lower specific activity and reproducibility than the purified immunoglobulin of the present invention (comparison shown in Figure 5). As used herein, the terms "purified" and "highly pure" or "highly purified" refer to immunoglobulins having the same or substantially the same specificity as the 4G10 antibody but showing a gel pattern similar to that exhibited by the immunoglobulins, or antibodies, of the present invention, especially in that they exhibit only a single heavy chain band, as shown in Figure 5, and not the doublet found for previously available 4G10 monoclonal antibody.

In one embodiment, highly pure or purified immunoglobulin of the present invention comprises a histidine tag region. Again, this embodiment commonly comprises two light chain components and two heavy chain components wherein said heavy chain components exhibit a single band on gel electrophoresis. In a specific embodiment, said histidine tag is part of the heavy chain component of said antibody or immunoglobulin.

In specific embodiments of the present invention, the isolated polypeptides disclosed herein may comprise tags or other markers, including specific sequences of amino acids, especially where said sequence is composed of histidine residues, for example, a run of 6 histidine residues (such as with the polypeptide of SEQ ID NO: 6), and any additional alterations in said polypeptide necessary for attaching said marker, such as said histidine sequence, to the polypeptides of the invention. Such sequences are commonly, but need not necessarily be, attached to the COOH-terminal of the polypeptide sequences disclosed herein. In addition, where said polypeptide is encoded by a polynucleotide of the present invention, a nucleotide sequence encoding said marker sequence, such as a nucleotide sequence encoding a histidine tag sequence, may be part of the polynucleotide sequences of the invention.

001050"534590

In specific embodiments of the present invention, the polypeptide having SEQ ID NO: 6 is an example of an amino acid sequence representing a heavy chain polypeptide according to the present invention wherein the C-terminal of said chain has attached thereto a hexapeptide sequence composed of histidine residues. Corresponding to this is the polynucleotide having the nucleotide sequence of SEQ ID NO: 3, which encodes the polypeptide of SEQ ID NO: 6, and comprises at its 3'-end a nucleotide sequence coding for said histidine tag sequence. Other markers, tags, and amino acid sequences, configurations, and the like, useful for tagging the polypeptide of interest will no doubt occur to those of skill in the art once possessed of the disclosure of the present invention.

In a specific embodiment, the highly pure or purified immunoglobulin of the present invention comprises a heavy chain component whose amino acid sequence is substantially the same as the sequence of SEQ ID NO: 4. In another specific embodiment, the purified or highly pure immunoglobulin of the present invention comprises a light chain component whose amino acid sequence is substantially the same as the sequence of SEQ ID NO: 5. In a preferred embodiment, the highly pure or purified immunoglobulin of the present invention comprises a heavy chain component whose amino acid sequence is substantially the same as the sequence of SEQ ID NO: 4 and a light chain component whose amino acid sequence is substantially the same as the sequence of SEQ ID NO: 5.

In other specific embodiments, the purified or highly pure immunoglobulin of the present invention comprises a heavy chain component whose amino acid sequence is substantially the same as the sequence of SEQ ID NO: 6. In a preferred embodiment, said sequence is that of SEQ ID NO: 6.

The present invention also relates to isolated polynucleotide sequences encoding the polypeptides of which the antibodies of the present invention are comprised.

5 Thus, the present invention relates to an isolated polynucleotide encoding a polypeptide as disclosed herein including the complements of such polynucleotides. The isolated polynucleotides of the present invention include cDNAs. In specific embodiments, such polynucleotides include the polynucleotides having the sequences of SEQ ID NOs. 1, 2, and 3 and
10 sequences sufficiently identical thereto so as to encode a protein substantially identical to the polypeptides of the immunoglobulins of the present invention. Such variability may also be due to the degeneracy of the genetic code.

15 In another aspect, the present invention also relates to a method of producing a highly purified immunoglobulin comprising the steps of:

 (a) inserting a histidine tag sequence at the C-terminal end of the heavy chain component of an immunoglobulin to be purified to produce a histidine tagged immunoglobulin;

20 (b) purifying said histidine tagged heavy chain polypeptide by immobilized metal affinity chromatography under neutral conditions and specifically preventing exposure of the immunoglobulin to acidic pH;

 (c) recovering the purified histidine tagged highly purified immunoglobulin.

25 The methods of the invention are further described in more detail in the methods and examples below. The methods of the present invention also contemplate purification schemes wherein the heavy chain component is produced by expression of a polynucleotide encoding said histidine tagged
30 heavy chain component, such as a cDNA encoding such a tagged chain. One

example of such a cDNA is the polynucleotide sequence of SEQ ID NO: 3. A novel aspect of the methods of purification disclosed herein is the use of neutral, or relatively neutral, pH conditions during the immobilized metal affinity chromatography (IMAC) step in that, avoidance of any acidic pH exposure preserves the immunoglobulin, thereby affording highly pure or purified immunoglobulins. Such methodology may be readily applied to the production of other highly purified immunoglobulins (i.e., antibodies), even those with specificities different from those of the present invention. In keeping with the disclosure herein, to be avoided are pH values of 6.5 and below, preferably 6.0 and below, most preferably 5.5 and below, especially 5.0 and below and most especially 4.0 and below.

In another aspect, therefore, the present invention is directed to an immunoglobulin produced by the methods of production and purification disclosed according to the present invention (as detailed above and in the examples).

In accordance with the present invention, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$\text{Percent Identity} = 100 [1 - (C/R)]$$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in

the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity. The alignment boundary is the length of the Reference Sequence or claimed sequence that is being compared.

The recombinant polynucleotides and polypeptides disclosed herein may be prepared by direct chemical synthesis thereof in light of the sequences disclosed or may be prepared by recombinant means well known in the molecular biological arts. Consequently, as used herein and except as noted otherwise, all terms are defined as given below.

In accordance with the present invention, the term "DNA segment" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component

nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA
5 may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids and/or such polypeptides, may be in "enriched form." As
10 used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences,
15 constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.

"Isolated" in the context of the present invention with respect to polypeptides (or polynucleotides) means that the material is removed from its
20 original environment (*e.g.*, the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living organism is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such
25 polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment. The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

30

The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in "purified" form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, claimed polypeptide which has a purity of preferably 0.001%, or at least 0.01% or 0.1%; and even desirably 1% by weight or greater is expressly contemplated.

15 The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding *in vivo* for the native expression product of the gene. The coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene,
20 wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

In accordance with the present invention, the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. Generally, DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

The term "expression product" means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).

5

The term "fragment," when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

10

The term "primer" means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

15 The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription.

The term "open reading frame (ORF)" means a series of triplets coding for amino acids without any termination codons and is a sequence (potentially) translatable into protein.

20

As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence.

25

Methods useful in the recombinant procedures disclosed herein are described in such compendiums as Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), Wu et

30

al, *Methods in Gene Biotechnology* (CRC Press, New York, NY, 1997), and *Recombinant Gene Expression Protocols*, in *Methods in Molecular Biology*, Vol. 62, (Tuan, ed., Humana Press, Totowa, NJ, 1997), the disclosures of which are hereby incorporated by reference in their entirety.

5

The present invention further relates to a functional, antigen-specific immunoglobulin molecule, which includes dimeric or tetrameric structures comprised of either a light and heavy chain, or two light plus two heavy chains. The highly pure or purified immunoglobulins of the present invention show a single band for the heavy chain on a gel as described in Figure 5 and as distinguished from the presently available 4G10 monoclonal antibody produced from 4G10 hybridoma cells. Of course, substitution of amino acids of similar size and chemical properties will alter the sequence of the light and heavy chain polypeptides making up the immunoglobulins of the present invention but will not produce distinctly separate bands on gels run as disclosed herein and thus will still differ from the presently known 4G10 monoclonal antibody.

In other embodiments, the present invention further relates to purified or highly pure immunoglobulins or monoclonal antibodies exhibiting the same or similar antigenic specificity as 4G10 monoclonal antibody and wherein said antibody demonstrates positive reactivity with phosphotyrosine containing proteins. In a one embodiment, such purified or highly pure immunoglobulins demonstrate:

- 25 (a) positive reactivity with phosphotyrosine containing proteins; and
 (b) lack of reactivity with phosphoserine or phosphothreonine proteins.

In other embodiments of the present invention, such immunoglobulins exhibit positive reactivity with phosphotyrosine-containing proteins from

animal cells, especially wherein the antibody demonstrates positive reactivity with phosphotyrosine-containing proteins from human cells.

5 The present invention also relates to vectors comprising a polynucleotide as disclosed herein and to recombinant or genetically engineered cells capable of expressing said polynucleotides after transfected or transformed with said vectors, most especially where the expressed polynucleotides result in polypeptides that are secreted from the cells.

10 In one embodiment, a cell is transfected with one or more of the vectors disclosed herein to form a recombinant cell that expresses the polynucleotides contained in said vector to form at least two different polypeptides wherein each polypeptide represents either the heavy or the light chain of an antibody according to the present invention. In such an
15 embodiment, a recombinant cell expresses a polynucleotide encoding a light chain and another polynucleotide encoding a heavy chain for an antibody according to the invention. Such antibodies are then assembled within the cell and secreted in a form capable of binding to an antigen.

20 Methods of genetically engineering such cells are well known in the literature [see, for example, the methods disclosed in Morrison et al, U.S. Patent 5, 807,715, the disclosure of which is hereby incorporated by reference in its entirety; see also Ochi et al, *PNAS*, **80**, 6351-55 (1983); Johnson, U.S. Patent 5,824,307]. Cells useful for such methods include
25 most lymphoid cells, such as myelomas, hybridomas, and plasmacytomas, as well as cell lines such as CHO cells.

Recombinant cells of the present invention include cells producing antibodies that demonstrate positive reactivity with phosphotyrosine-
30 containing proteins from human cells.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the *E. coli. lac* or *trp*, the phage lambda P_L

promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying
5 expression.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance
10 for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E. coli*.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be
15 employed to transform an appropriate host to permit the host to express the protein.

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, *Streptomyces*, *Salmonella*
20 *typhimurium*; fungal cells, such as yeast; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

More particularly, the present invention also includes recombinant
25 constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct
30 further comprises regulatory sequences, including, for example, a promoter,

operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pBluescript SK, pBSKS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

10

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_R, P_L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

20

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

25

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

30

Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

5 Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition,
10 Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence
15 into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

20

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* Trp1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a
25 downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader
30 sequence capable of directing secretion of translated protein into the

periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

5

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

25

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

30

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

5 Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.

10 Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines.

15 Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be

20 used to provide the required nontranscribed genetic elements.

 The polypeptides, or antibodies, of the present invention are recovered and purified from recombinant cells as disclosed herein. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein.

25 Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps as well as IMAC (immobilized metal affinity chromatography).

 A polypeptide of the present invention may be a naturally purified

30 product, or a product of chemical synthetic procedures, or produced by

recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

The present invention also relates to an immunosorbent material comprising the purified or highly pure immunoglobulins as disclosed herein and a microporous polymeric substrate. In one embodiment, such microporous polymeric substrate comprises a plurality of beads, said beads having diameters on the order of no larger than about 100 microns, preferably no larger than about 10 microns, most preferably about 5 microns with an especially preferred embodiment using beads 5 microns (or micrometers) in diameter. In a specific embodiment of the present invention, the substrate is polymerized agarose.

In another embodiment using such microporous polymeric substrate, such as the aforementioned plurality of beads, such substrate comprises one or more metal ions, or other metal ligands, which metal ligands bind the histidine tagged portion of a histidine tagged antibody. Such an antibody may be the histidine tagged antibody of the invention. As described herein, such antibodies are commonly highly pure or purified (meaning an antibody with the same or similar degree of purity of that antibody disclosed herein as determined, for example, by the gel pattern shown for the purified or highly pure 4G10-specific antibody of the invention). Such a ligand-attached substrate (serving as a metal affinity matrix, i.e., a surface comprising a metal ligand capable of binding to a histidine tagged protein, such as an antibody, especially a histidine tagged 4G10-specific antibody of the present invention) is useful for attaching to the histidine-tagged portion of the

antibodies of the present invention in methods other than just for purification. Thus, such methods are easily adapted to assay and screening processes and are not limited to purification schemes although other and different uses will no doubt suggest themselves to those skilled in the art yet
5 such uses are still within the methods disclosed according to the present invention.

In accordance with the foregoing, the present invention further relates to a method of detecting the presence of phosphotyrosine-containing
10 proteins in a sample comprising the steps of contacting the sample with an antibody of the present invention and testing for reactivity wherein a positive reaction demonstrates the presence of a phosphotyrosine-containing protein or polypeptide in said sample.

Specific embodiments of the present invention comprise methods wherein the step of testing the sample further comprises contacting the sample with an immunosorbent material which includes the monoclonal antibodies. In preferred embodiments, the step of testing further comprises testing by a method selected from the group consisting of
15 immunofluorescence, radioimmunoassay, immunoprecipitation, complement
20 fixation, competitive reaction, Western blotting, immunohistochemistry, flow cytometry, and enzyme-linked immunosorbent assay (ELISA).

The monoclonal antibodies of the present invention serve as a high
25 titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins, with potential uses in diagnosis of a variety of diseases, including certain cancers. The antibodies, which have demonstrated affinity for a variety of molecules containing phosphotyrosine residues, were prepared recombinantly from

corresponding cDNAs and have properties indistinguishable from those of commercially available antibodies produced by the 4G10 hybridoma cell line.

Among the utilities for the antibodies disclosed according to the present invention include applications to identify cellular substrates for tyrosine kinases and make possible the affinity purification of a wide variety of phosphotyrosine-proteins, including clinical and diagnostic assays for such things as platelet-derived growth factors (PDGF - and its cellular receptor), TGF (tumor growth factor) and determining the tyrosine phosphorylation status of one or multiple proteins in a given cell or tissue sample.

In one non-limiting example of such utility, a cell or tissue sample can be reacted with the monoclonal antibodies of the present invention and the immune complex of monoclonal antibody bound to proteins containing phosphotyrosines collected. Such an immunoprecipitation or immunoaffinity purification complex can be resolved and reacted by a variety of procedures (e.g. Western blotting, ELISA) with antibodies to the various known proteins to identify the phosphotyrosine proteins in the given sample. This analysis can be extended to the discovery of novel phosphotyrosine proteins by scaling up the immunoprecipitation or immunoaffinity purification and purifying the phosphotyrosine proteins and subjecting them to analytical procedures such as protein sequencing by Edman degradation or mass spectrometry. A further example of the aforementioned embodiment involves the immunoprecipitation or immunoaffinity purification of a known protein or proteins and reacting the resulting complex with the monoclonal antibodies of the present invention for determining phosphotyrosine status.

In a simple TGF assay method, a biological fluid, such as urine or blood serum, or other potential source of TGF from a patient can be reacted with a preparation of EGF receptors, for example, cell membranes from

examples, it should be kept clearly in mind that other and different embodiments of the methods disclosed according to the present invention will no doubt suggest themselves to those of skill in the relevant art.

Example

5

Abbreviations: IP, immunoprecipitation; HC, heavy chain; LC, light chain; IgG, immunoglobulin; Mab, monoclonal antibody; ELISA, enzyme-linked immunosorbent assay; IMAC, Immobilized Metal Affinity Chromatography; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; HRP, 10 horseradish peroxidase; ECL, enhanced chemiluminescence; PBS, phosphate buffered saline; nt, nucleotide; EGF, epidermal growth factor; EGFr epidermal growth factor receptor; CHO, Chinese Hamster Ovary;

The definitions of nomenclature and descriptions of general laboratory 15 procedures used in this application can be found in Ausubel, F.M. *et al.*, Current Protocols In Molecular Biology. Wiley Interscience, New York, NY. 1999. All kits and enzymes were used according to the manufacture's instructions.

20 Preparation of Cell Lysates

Adherent human A431 cells were twice washed with cold PBS and subsequently lysed with ice-cold modified RIPA buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% Na-deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 microgram/ml each Aprotinin, leupeptin, pepstatin; 1 mM Na₃VO₄; 1 25 mM NaF; 1 ml per 10⁷ cells/100 mm dish) by scraping cells off the dish with a plastic cell scraper. The cell suspension was transferred into a centrifuge tube and gently rocked at 4 °C for 15 minutes to lyse the cells. Lysates are centrifuged at 14,000 x g for 15 minutes and the supernatant immediately transferred to a fresh tube. Protein concentration was

determined with a Coomassie-based reagent (Coomassie® Plus Protein Assay Reagent, Pierce, Rockland, IL).

Immunoblotting (Western Blotting)

5 Twenty µg of cell lysates per individual lane were subjected to SDS-PAGE and proteins transferred to a nitrocellulose membrane. The nitrocellulose membrane is washed twice with distilled H₂O and stained with Ponceau Red solution for 5 minutes to visualize protein bands. The molecular weight markers are marked with a ball point pen and the membrane blocked
10 in freshly prepared PBS containing 3% nonfat dry milk for 20 minutes at room temperature with constant agitation. Primary antibody (native or recombinant 4G10) is diluted in PBS/3% nonfat dry milk and incubated with the membrane for 1 to 2 hours at room temperature or overnight at 4 °C. The nitrocellulose membrane is washed five times for 3 to 5 minutes each
15 with PBS containing 0.05% Tween 20 before incubation with the secondary antibody (goat-anti-mouse HRP conjugate) for 1 hour. The membrane is washed five times again before final detection of proteins with an ECL HRP substrate.

20 Mouse IgG ELISA.

To measure levels of recombinant antibody in conditioned media, a mouse IgG ELISA was developed using precoated 96 well protein G strip plates (Pierce, Rockland, IL). Standards or samples are added in a 100 µl volume to wells and incubated at 37 °C for 1 hour and then washed with
25 PBS prior to adding PBS 3% non-fat milk for 30 min at 37 °C. The plates are washed again and 100 µl of a anti-mouse HRP secondary antibody is added for 1 hour at 37 °C. Wells are then washed 3X in PBS and developed with TMB substrate solution (Pierce, Rockland, IL), stopped with 50 µl of 2 N H₂SO₄, and absorbance at 450 nm determined.

Immunoprecipitation.

A Protein A agarose bead slurry is washed twice with PBS and
5 restored to a 50% slurry with PBS. The cell lysate is precleared by adding
100 microliters of the protein A agarose slurry per 1 ml of cell lysate and
incubating at 4 °C for 10 minutes on a orbital shaker. The protein A beads
are removed by centrifugation at 14,000 x g at 4 °C for 10 minutes and
supernatant transferred to a fresh centrifuge tube. The cell lysate is diluted
10 with PBS to approximately 1 mg/ml total cell protein before addition of the
immunoprecipitating antibody (IP-antibody) in a total volume of 500
microliters. The cell lysate/antibody mixture is incubated for 2 hours or
overnight at 4 °C on an orbital shaker. The immuno-complex is captured by
adding 100 microliters of the protein A agarose slurry and incubated for
15 either 1 hour or overnight at 4 °C on an orbital shaker. The protein A bead-
bound immuno-complex is collected by centrifugation for 5 seconds at
14,000 rpm and the supernatant discarded. The beads are washed 3 times
with 800 microliters ice-cold modified RIPA buffer and then resuspended in
60 microliters of SDS-PAGE reducing buffer and boiled for 5 minutes to
20 dissociate the immunocomplexes from the beads. The beads are collected by
centrifugation and SDS-PAGE is performed with the supernatant fraction.

Cloning, Expression and Purification of the recombinant 4G10 monoclonal 25 Antibody.

In order to clone the antibody heavy chain (HC) and light chain (LC)
cDNAs from the 4G10 hybridoma cell line, two 5' oligonucleotide primers

were designed based on the N-terminal amino acid sequencing of the LC and HC purified peptides. The HC 5' coding strand primer RAPHC-5

5'-GCC ACC ATG GAA TGG AGT TGG ATA TTT CTC TTT CTC CTG TCA
5 GGA ACT GCA GGT GTC CAC TCT GAG GTC CAG CTG CAR CA

(SEQ ID NO: 7)

consisted of 63 base oligonucleotide encoding the N-terminal leader
10 secretion signal sequence with a Kozak translation initiation site fused to the
first 17 nt (nucleotide) encoding the mature processed N-terminal HC. The
LC 5' coding strand primer RAPLC-5

5'-GCC ACC ATG GAT TTT CTG GTG CAG ATT TTC AGC TTC TTG CTA
15 ATC AGT GCC TCA GTT GCA ATG TCC AGA GGA GAA AAT GT

(SEQ ID NO: 8)

consisted of A 63 base oligonucleotide encoding the N-terminal leader
20 secretion signal sequence with a Kozak translation initiation site fused to the
first 17 nucleotides encoding the mature processed N-terminal LC.

Design of the HC 3' non-coding strand primer

25 5'- CTA AGC TCA TTT ACC CGG AGA CCG (SEQ ID NO: 9)

for amplification of the C-terminal encoding portion of the HC cDNA was
based on prior knowledge that the 4G10 monoclonal antibody HC constant
region was of the class γ 2b. Design of the LC 3' non-coding strand primer

30

5'-CTC AGG ACC TTT GTC TCT AAC ACT C (SEQ ID NO: 10)

for amplification of the C-terminal encoding portion of the LC cDNA was based on prior knowledge that the 4G10 monoclonal antibody LC constant
5 region was of the class kappa. Oligonucleotides were synthesized by IDT (Integrated DNA Technologies Inc., Coralville, IA) using standard DNA synthesis chemistries.

Total RNA was purified from PBS washed snap-frozen 4G10
10 hybridoma cell pellets (approximately 1×10^7 cells per sample) using RNAzolTMB (Tel-Test Inc, Friendswood, TX). Purified total RNA was ethanol precipitated and quantified by absorbance at 260 nm. First strand cDNA was synthesized by reverse transcribing 2 μ g of total RNA with oligo(dT) using the SuperScriptTM system (Gibco BRL, Gaithersburg, MD). The
15 ExpandTM High Fidelity PCR system (Boehringer Mannheim, Indianapolis, IN) was used for polymerase chain reaction (PCR) amplification of 1 μ l of newly made first strand cDNA. PCR amplification conditions were as follows: after heating PCR components to 94°C, 1 μ l of cDNA was added to each tube. Subsequent cycling conditions were 94°C for 15 s, 50°C for 1 min, and
20 72°C for 1 min for 17 cycles for LC amplification and 21 cycles for HC amplification with a final extension of 72°C for 10 min. LC and HC PCR products were purified from ethidium bromide stained agarose gels and cloned into the eukaryotic expression vector pcDNA3.1 (Invitrogen Corporation, San Diego, CA) and transformed into *E. coli* competent cells
25 according to the manufacture's instructions. For each LC or HC plasmid construct, at least 4 individual *E.coli* plasmid clones were sequenced by standard automated DNA sequencing methods and the nucleotide consensus sequence minus the N-terminal leader secretion signal sequence are described in SEQ ID NO: 1 and SEQ ID NO: 2. The deduced polypeptide

sequence translated from SEQ ID NO: 1 and SEQ ID NO: 2 are designated SEQ ID NO: 3 and SEQ ID NO: 4.

A hexa-histidine sequence was added to the C-terminus of the HC clone pHC-42 by site directed mutagenesis using a commercial kit (QuickChange™, Stratagene, La Jolla, CA) according to the manufacture's instructions. The following complementary oligonucleotides were used for introducing the hexa-histidine sequence: coding strand primer HC-His 5'

5'-CTC CCG GTC TCC GGG TAA AGG TGG CCA TCA CCA CCA TCA CCA
TTG AGC TTA GAA GGG CAA TT

(SEQ ID NO: 11)

and non-coding strand primer HC-His 5'

5'-AAT TGC CCT TCT AAG CTC AAT GGT GAT GGT GGT GAT GGC CAC
CTT TAC CCG GAG ACC GGG AG-3'

(SEQ ID NO: 12)

Successful introduction of the hexa-histidine encoding region was confirmed by DNA sequencing and corresponds to the polynucleotide sequence of SEQ ID NO: 3 which encodes the polypeptide of SEQ ID NO: 6.

The ability of the cloned HC and LC cDNAs to produce a secreted functional recombinant monoclonal antibody capable of recognizing phosphotyrosine containing proteins was initially examined by transiently transfecting African green monkey COS cells. HC and LC plasmids were transiently transfected into COS cells using the transfection agent Lipofectamine (Life Technologies, Gaithersburg, MD) and the conditioned media collected 3 to 5 days later. The human epidermoid carcinoma cell line

A431 was used to monitor the ability of the recombinant antibody to specifically recognize phosphotyrosine containing cellular proteins. A431 overexpress the Epidermal Growth Factor receptor (EGFr) and upon stimulation with EGF there is a marked increase in phosphorylation of tyrosine residues in the cytoplasmic signal transducing region of the EGFr as well as many other proteins that are components of the signaling cascade downstream of the EGFr (Hunter, T. and Cooper, J.A., *Cell* **3**:741-52 (1981); Goldkorn, T. et al., *J. Biol. Chem.*, **266**(24):16092-7 (1991); Moghal, N., et al., *Curr Opin Cell Biol.* **2**:190-6 (1999). The ability of the secreted recombinant 4G10 monoclonal antibody to recognize phosphotyrosine proteins was determined by immunoblotting total protein cell lysates of EGF stimulated A431 cells. Figures 1 and 2 clearly demonstrate that the conditioned media from COS cells co-transfected with LC and HC plasmids or LC and HC His-tagged plasmids recognized the same complex pattern of phosphotyrosine containing proteins that native 4G10 recognizes. Conditioned media from empty vector transfection controls and secondary antibody alone did not recognize any protein bands from the EGF stimulated A431 immunoblots. Furthermore, the addition of 50 mM phenylphosphate, a competitive inhibitor of phosphotyrosine binding to 4G10, completely blocked recognition of A431 phosphotyrosine containing proteins.

In order to produce sufficient quantities of r4G10 for commercial sale, stable transfected Chinese Hamster Ovary (CHO) cell lines were generated. CHO cells are routinely used for making recombinant monoclonal antibodies (Trill, J.R. et. al., *Current Opinion in Biotechnology*, **6**:553-560, 1995) and several high expressing cell lines were generated by transfection and selection by the method of Page and Sydenham (*Biotechnology*, **9**:64-68, 1991). Briefly, the mouse dihydrofolate reductase (DHFR) cDNA (Subramani, S. et. al., *Mol. Cell. Biol.* **1**:854-864) was cloned into the LC expression plasmid such that it replaced the Neomycin resistance cassette of

pcDNA3.1 whereas the HC expression plasmid retained the Neomycin resistance cassette. After co-transfection transformants were selected for the double phenotype of dhfr⁺/neo resistance and colonies were pooled. To select for clones that produced high amounts of recombinant antibody, the pooled clones were cultured in the presence of 10⁻⁷ M methotrexate, a competitive inhibitor of DHFR that allows for amplification of the integrated linked HC and LC expression cassettes. Individual clones that survived methotrexate were expanded and secreted antibody production measured by an anti-IgG ELISA. High r4G10 antibody producing clones were subjected to a further round of amplification by culturing in the presence of 10⁻⁶ M methotrexate and again clones secreting high levels of antibody were identified by the anti-IgG ELISA.

The high producing his-tagged r4G10 CHO clones were cultured in spinner flasks or bioreactors and conditioned media pooled for antibody purification. Approximately 400 ml of CHO-4G10 conditioned media was equilibrated by adding 100 ml of 2.5 M NaCl, Sodium Phosphate pH 8.0. A 12 ml Nickel-IDA column was equilibrated with 5 column volumes of 0.5 M NaCl, 0.05 M Sodium Phosphate pH 8.0 before the sample was passed over the column once. The column was washed with 30 column volumes of 0.5 M NaCl, 0.05 M Sodium Phosphate pH 8.0 and then washed with 5 column volumes of 90% Buffer A (0.5 M NaCl, 0.05 M Sodium Phosphate pH 8.0) and 10% Buffer B (0.5 M NaCl, 0.05 M Sodium Phosphate pH 8.0 0.5 M Imidazole). Recombinant 4G10 was eluted with a 5 column volume linear gradient starting with 90% Buffer A, 10% Buffer B finishing with 100% Buffer B. Eluted fractions were collected in 2 ml tubes containing 50 mM EDTA pH 8.0 to 5% of their programmed volume. As determined by an IgG ELISA, the antibody eluted in the range of 150-250 mM Imidazole and was greater than 95% pure as assessed by SDS-PAGE. Peak fractions were

pooled, dialyzed, concentrated, and buffer conditions adjusted to 1X PBS, pH 7.5, 0.02% sodium azide before the addition of glycerol to 30%.

Purified r4G10 was analyzed for its ability to recognize
5 phosphotyrosine containing proteins. Figure 3 demonstrates that the ability
of r4G10 to immunoprecipitate phosphotyrosine containing proteins from
EGF stimulated A431 cell lysates is comparable to native 4G10. Figure 4
demonstrates that probing an immunoblot of A431 cell lysates with
purified r4G10 recognizes the unique pattern of phosphotyrosine containing
10 proteins that is recognized by native 4G10.

15 **Determination of 4G10 purity by SDS Page**

His-tagged recombinant 4G10 was purified as described and subjected
to SDS-PAGE for determination of the number of polypeptides and their
approximate molecular weights. A PAGE-ONE 4/20% polyacrylamide gel
(Owl Separation Systems, Portsmouth, NH) was used for electrophoretic
20 separation of proteins according to the method of Laemmli (Laemmli, U.K.,
1970, Nature, 227, p680). Protein samples were prepared by adding 6µl of
each protein(1µg/µl) to 4µl dH₂O (distilled water) and 10µl 2X Sample Buffer
(Sigma, St. Louis, MO). Samples were boiled for 5 min, centrifuged briefly,
and 20 µl of each boiled sample was loaded on the gel. The gel was
25 electrophoresed using 800 ml of running buffer (3 gr/L Tris base, 14.4 gr/L
Glycine, 1 g/L SDS) with 40mAmps of current for 2 hrs. The gel was then
removed from its casing and rocked in dH₂O for 5 min. Bio-Safe Coomassie
(Bio-Rad Laboratories, Hercules, California) was then used to stain the gel.
Staining consisted of rocking the gel in the Coomassie for 30 min. The

subsequent destaining consisted of three, 10 min. washes with dH₂O, while gently rocking the gel. Finally, the gel was dried between two sheets of cellulose on a gel drying frame (Diversified Biotech, Boston, MA).

5 The antibody of the present invention was purified according to the already described procedure. For the His-tagged recombinant 4G10 the purification procedure is performed under pH neutral conditions without exposing the antibody to acidic solutions that are detrimental to antibody phosphotyrosine binding activity and represents a novel purification
10 approach. This method, employing neutral or near-neutral pH, is also useful in purifying other antibodies as well as the 4G10-specific antibody of the present invention. The non-tagged antibody is prepared from the tagged antibody by removal of the tag or by Protein A affinity chromatography as is currently done for the native 4G10 product. A convenient protocol follows.

15

Purification of 4G10 by Protein A Affinity Chromatography

Two hundred ml of clarified Conditioned medium is loaded twice on to a 5 ml packed volume Protein A column at a flow rate of 2ml/min. The
20 column is then washed with 400 ml of PBS and eluted with 15 ml of pH 2.7 Elution buffer (50mM Glycine, pH 2.7) and 1 ml fractions that have been pre-spiked with 100 microliters of neutralization buffer (1M Tris, 1.5M NaCl, 1mM EDTA, 0.5% sodium azide) are collected. Fractions are immediately mixed after collecting to ensure prompt neutralization. The antibody peak
25 fractions are pooled and diluted to 1 mg/ml prior to use.

Additional General References:

1. Cohen, B., *et al.*, Proc. Natl. Acad. Sci. USA. **87**: 4458-4462, 1990.
2. Druker, B.J., *et al.*, New Eng. J. Med. **321**: 1383-1391, 1989.
- 30 3. Kanakura, Y., *et al.*, J. Biol. Chem. **266**: 490-495, 1991.

WHAT IS CLAIMED IS:

1. A purified or highly pure immunoglobulin having the same specificity as 4G10 monoclonal antibody.

5

2. The purified or highly pure immunoglobulin of claim 1 comprising two light chain components and two heavy chain components wherein said heavy chain components exhibit a single band on gel electrophoresis.

10 3. The purified or highly pure immunoglobulin of claim 1 wherein said immunoglobulin comprises a histidine tag region.

15 4. The purified or highly pure immunoglobulin of claim 3 comprising two light chain components and two heavy chain components wherein said heavy chain components exhibit a single band on gel electrophoresis.

5. The purified or highly pure immunoglobulin of claim 4 wherein said histidine tag is part of the heavy chain component of said antibody.

20 6. The purified or highly pure immunoglobulin of claim 1 further comprising a heavy chain component whose amino acid sequence is substantially the same as the sequence of SEQ ID NO: 4 and a light chain component whose amino acid sequence is substantially the same as the sequence of SEQ ID NO: 5.

25

7. The purified or highly pure immunoglobulin of claim 1 further comprising a light chain component whose amino acid sequence is the sequence of SEQ ID NO: 5 and whose heavy chain component is the sequence of SEQ ID NO: 4.

30

8. The purified or highly pure immunoglobulin of claim 2 further comprising a heavy chain component whose amino acid sequence is substantially the same as the sequence of SEQ ID NO: 6 and a light chain component whose amino acid sequence is the sequence of SEQ ID NO: 5.

5

9. An isolated recombinant polynucleotide encoding a polypeptide of claims 6, 7, and 8.

10. The isolated recombinant polynucleotide of claim 9 wherein said polynucleotide is a cDNA.

11. The complement of claim 9 or 10.

12. A vector comprising a polynucleotide of claim 9, 10, and 11.

15

13. A recombinant cell comprising the vector of claim 12 wherein said cell expresses the polypeptide encoded by the polynucleotide in said vector.

14. The recombinant cell of claim 13 wherein said cell also secretes an immunoglobulin.

20

15. The recombinant cell of claim 14 wherein the expressed polypeptide is an antibody specific for an antigen.

16. The recombinant cell of claim 15 wherein said antibodies demonstrate positive reactivity with phosphotyrosine-containing proteins from human cells.

25

17. An immunosorbent material comprising the monoclonal antibodies of claim 2 or claim 4 and a microporous polymeric substrate.

30

18. The immunosorbent material of claim 17 wherein the substrate is a plurality of beads wherein said beads are no larger than about 100 microns in diameter.

5

19. The immunosorbent material of claim 17 wherein the substrate is a plurality of beads wherein said beads are no larger than about 10 microns in diameter.

10

20. The immunosorbent material of claim 17 wherein the substrate is a plurality of beads wherein said beads are about 5 microns in diameter.

21. The immunosorbent material of claim 18 wherein the substrate is polymerized agarose.

15

22. The immunosorbent material of claim 17 wherein the substrate comprises a metal ligand capable of binding to the histidine-tagged portion of a protein.

20

23. The immunosorbent material of claim 22 further comprising a chemical linkage between said metal ligand and the antibodies of claim 17.

24. A method of detecting the presence of phosphotyrosine-containing proteins in a sample comprising the steps of contacting the sample with an antibody of claim 1 or 2 and testing for reactivity wherein a positive reaction demonstrates the presence of a phosphotyrosine-containing protein or polypeptide in said sample.

25

25. The method of claim 24 wherein the step of testing the sample further comprises contacting the sample with an immunosorbent material which includes the monoclonal antibodies.

5 26. The method of claim 24 wherein the step of testing further comprises testing by a method selected from the group consisting of immunofluorescence, radioimmunoassay, immunoprecipitation, complement fixation, competitive reaction, Western blotting, immunohistochemistry, flow cytometry, and enzyme-linked immunosorbent assay (ELISA).

10 27. A method of producing a purified or highly pure immunoglobulin comprising the steps of:

 (a) inserting a histidine tag sequence at the C-terminal end of the heavy chain component of an immunoglobulin to be purified to produce a
15 histidine tagged immunoglobulin;

 (b) purifying said histidine tagged heavy chain polypeptide by immobilized metal affinity chromatography under neutral conditions and specifically preventing exposure of the immunoglobulin to acidic pH;

 (c) recovering the purified histidine tagged highly purified
20 immunoglobulin.

28. The method of claim 27 wherein said histidine tagged heavy chain component is produced by expression of a polynucleotide encoding said histidine tagged heavy chain component.

25 29. The method of claim 27 wherein said pH in step (b) is not permitted to go below a pH of 5.0.

30 30. The method of claim 27 wherein said pH in step (b) is not permitted to go below a pH of 6.0.

31. The method of claim 27 wherein the antibody being purified is the antibody of claim 4.

5 32. The immunoglobulin produced by the method of claim 27, 28, 29 or 30.

10

15

20

25

30

5

Variable	Mean	SD	Min	Max
Age	34.5	12.5	18	65
Gender	Male	Female		
Marital Status	Married	Single		
Education	High School	College		
Occupation	Manager	Worker		
Income	\$20,000	\$40,000		
Health Status	Good	Fair		
Exercise Frequency	Weekly	Monthly		
Stress Level	Low	High		
Sleep Quality	Good	Poor		
Dietary Habits	Healthy	Unhealthy		
Alcohol Consumption	Occasional	Frequent		
Tobacco Use	Non-user	User		
Family Size	2	3		
Home Ownership	Owner	Renter		
Commute Time	15 min	30 min		
Work Hours	40 hrs	50 hrs		
Job Satisfaction	High	Low		
Life Satisfaction	High	Low		
Overall Well-being	Good	Fair		

Fig. 1




Fig. 2




Fig. 3




Fig. 4





Fig. 5



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

A RECOMBINANT MONOCLONAL ANTIBODY TO PHOSPHOTYROSINE-CONTAINING PROTEINS

the specification of which [X] is attached hereto or [] was filed on _____ as Application Serial No. _____ and was amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s):

(Number)	(Country)	(Day/Month/Year Filed)	Priority Claimed	
			Yes	No
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, Section(s) 119 and/or 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: John N. Bain (Reg. No. 18,651); John G. Gilfillan, III (Reg. No. 22,746); Elliot M. Olstein (Reg. No. 24,025); Raymond J. Lillie (Reg. No. 31,778); William Squire (Reg. No. 25,378); and Alan J. Grant (Reg. No. 33,389). Address correspondence and telephone calls to:

Alan J. Grant, Esq. c/o Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 - (973) 994-1700.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: _____ Dominic Eisinger

Inventor's signature: _____ Date: _____
Residence: East Hill Road, Keene, NY 12942 _____ Citizenship: USA _____
Post Office Address: same _____

Full name of second joint inventor _____ Lynn Stiles

Inventor's signature: _____ Date: _____
Residence: 3 McKenzie Pond Road, Saranac Lake, NY 12983 _____ Citizenship: USA _____
Post Office Address: same _____

A RECOMBINANT MONOCLONAL ANTIBODY TO PHOSPHOTYROSINE-CONTAINING PROTEINS

Full name of sole or first inventor: Arthur LaMarche

Inventor's signature: _____ Date: _____
Residence: 26 Lake View St., Lake Placid, NY 12946 Citizenship: USA
Post Office Address: same

Full name of second joint inventor Thomas Jelinek

Inventor's signature: _____ Date: _____
Residence: 32 Holly Hill Road, Lake Placid, NY 12946 Citizenship: Canada
Post Office Address: same

Docket No: 724650-3

004060 "33465030

SEQUENCE LISTING

<110> Eisinger, Dominic P.
Stiles, Lynn
LaMarche, Arthur
Jelinek, Thomas

<120> Recombinant Monoclonal Antibody Specific for
Phosphotyrosine-Containing Proteins

<130> 724650-3

<140>

<141>

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 1365

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:cDNA for heavy
chain of recombinant antibody

<400> 1

```
gagggtccagc tgcarcagtc tggacctgaa ctggtgaagc ctggggcttc agtgatgata 60
tctctgcagga cttctgcata cacattcact gaaaacaccg tgcactgggt gaagcagagc 120
catggagaga gccttgagtg gattggagggt attaatcctt actatgggtg ttctatcttc 180
agcccgaagt tcaagggcaa ggccacattg actgtagaca agtcctccag cacagcctac 240
atggagctcc gcagcctgac atctgaggat tctgcagtct attactgtgc aagaagggct 300
ggggcgact actttgacta ctggggccaa ggcaccactc tcacagtctc ctcagccaaa 360
acaacacccc catcagtcta tccactggcc cctgggtgtg gagatacaac tggttcctcc 420
gtgactctgg gatgcctggt caagggctac ttccctgagt cagtgactgt gacttggaac 480
tctggatccc tgtccagcag tgtgcacacc ttcccagctc tctgcagtc tggactctac 540
actatgagca gctcagtgac tgtccccctc agcacctggc caagtcagac cgtcacctgc 600
agcgttgctc acccagccag cagcaccacg gtggacaaaa aacttgagcc cagcgggccc 660
atttcaacaa tcaacccctg tcctccatgc aaggagtgtc acaaagtccc agtcctaac 720
ctcgagggtg gaccatccgt cttcatcttc cctccaaata tcaaggatgt actcatgatc 780
tccttgacac ccaaggtcac gtgtgtggtg gtggatgtga gcgaggatga cccagacgtc 840
cagatcagct ggtttgtgaa caacgtggaa gtacacacag ctcagacaca aaccataga 900
gaggattaca acagtactat ccgggtggtc agcacccctc ccatccagca ccaggactgg 960
atgagtggca aggagttaa atgcaaggtc aacaacaaag acctcccatc acccatcgag 1020
agaaccatct caaaaattaa agggctagtc agagctccac aagtatacat cttgccgcca 1080
ccagcagagc agttgtccag gaaagatgtc agtctcactt gcctggtcgt gggcttcaac 1140
```

cctggagaca tcagtgtgga gtggaccagc aatgggcata cagaggagaa ctacaaggac 1200
accgcaccag tcctggactc tgacggttct tacttcatat atagcaagct caatatgaaa 1260
acaagcaagt gggagaaaac agattccttc tcatgcaacg tgagacacga gggctctgaaa 1320
aattactacc tgaagaagac catctcccgg tctccgggta aatga 1365

<210> 2

<211> 645

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:cDNA for light
chain of recombinant antibody

<400> 2

gaaaatgtgc tcaccagtc tccagcaatc atgtctgcat ctccagggga aaaggtcacc 60
atgacctgca gggccagctc aagtgttaagt tccagttact tgcactggta tcggcagaag 120
tcaggtgcct cccccaact ctggatttat agcacatcca acttggcttc tggagtcctt 180
gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagtgtggag 240
gctgaagatg ctgccactta ttactgccag cagtacagtg gttaccggac gttcgggtgga 300
ggcaccaagc tggaaatcaa acgggctgat gctgcaccaa ctgtatccat cttcccacca 360
tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac 420
cccagagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tgggtgtcctg 480
aacagttgga ctgatcagga cagcaaagac agcacctaca gcatgagcag caccctcaca 540
ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca 600
tcaacttcac ccatcgtaaa gagcttcaac aggaatgagt gttag 645

<210> 3

<211> 1389

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:cDNA for heavy
chain of recombinant antibody with 3'-histidine
tag sequence

<400> 3

gaggctccagc tgcarcagtc tggacctgaa ctggtgaagc ctggggcttc agtgatgata 60
tcctgcagga cttctgcata cacattcact gaaaacaccg tgcactgggt gaagcagagc 120
catggagaga gccttgagtg gattggagggt attaatecctt actatgggtg ttctatcttc 180
agcccgaagt tcaagggcaa ggccacattg actgtagaca agtcctccag cacagcctac 240
atggagctcc gcagcctgac atctgaggat tctgcagtctt attactgtgc aagaagggct 300
ggggcgact actttgacta ctggggccaa ggcaccactc tcacagtctc ctcagccaaa 360
acaacacccc catcagtcta tccactggcc cctgggtgtg gagataaac tggttcctcc 420
gtgactctgg gatgcctggt caagggctac ttccctgagt cagtgactgt gacttggaaac 480

tctggatccc tgtccagcag tgtgcacacc ttcccagctc tcctgcagtc tggactctac 540
 actatgagca gctcagtgac tgtccctccc agcacctggc caagtcagac cgtcacctgc 600
 agcgttgctc acccagccag cagcaccacg gtggacaaaa aacttgagcc cagcggggccc 660
 atttcaacaa tcaacccctg tcctccatgc aaggagtgtc acaaagtcgc agtcctaac 720
 ctcgagggtg gaccatccgt ctccatcttc cctccaaata tcaaggatgt actcatgac 780
 tccctgacac ccaagggtcac gtgtgtggtg gtggatgtga gcgaggatga cccagacgtc 840
 cagatcagct ggtttgtgaa caacgtggaa gtacacacag ctgagacaca aacccataga 900
 gaggattaca acagtactat ccgggtgggtc agcacctccc ccattccagca ccaggactgg 960
 atgagtggca aggagttaa atgcaagggtc aacaacaaag acctcccatc acccatcgag 1020
 agaaccatct caaaaattaa agggctagtc agagctccac aagtatacat cttgccgcca 1080
 ccagcagagc agttgtccag gaaagatgtc agtctcactt gcctgggtcgt gggcttcaac 1140
 cctggagaca tcagtgtgga gtggaccagc aatgggcata cagaggagaa ctacaaggac 1200
 accgcaccag tcctggactc tgacggttct tacttcatat atagcaagct caatatgaaa 1260
 acaagcaagt gggagaaaaac agattccttc tcatgcaacg tgagacacga gggctctgaaa 1320
 aattactacc tgaagaagac catctcccgg tctccgggta aagggtggcca tcaccaccat 1380
 caccattga 1389

<210> 4

<211> 454

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Amino acid
 sequence for heavy chain of recombinant antibody

<400> 4

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Met Ile Ser Cys Arg Thr Ser Ala Tyr Thr Phe Thr Glu Asn
 20 25 30

Thr Val His Trp Val Lys Gln Ser His Gly Glu Ser Leu Glu Trp Ile
 35 40 45

Gly Gly Ile Asn Pro Tyr Tyr Gly Gly Ser Ile Phe Ser Pro Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Arg Ala Gly Ala Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110

Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro
 115 120 125
 Leu Ala Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
 130 135 140
 Cys Leu Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn
 145 150 155 160
 Ser Gly Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln
 165 170 175
 Ser Gly Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr
 180 185 190
 Trp Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser
 195 200 205
 Thr Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile
 210 215 220
 Asn Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn
 225 230 235 240
 Leu Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp
 245 250 255
 Val Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp
 260 265 270
 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn
 275 280 285
 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn
 290 295 300
 Ser Thr Ile Arg Val Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp
 305 310 315 320
 Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro
 325 330 335
 Ser Pro Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala
 340 345 350
 Pro Gln Val Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys
 355 360 365

Asp Val Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile
 370 375 380

Ser Val Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp
 385 390 395 400

Thr Ala Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys
 405 410 415

Leu Asn Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys
 420 425 430

Asn Val Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile
 435 440 445

Ser Arg Ser Pro Gly Lys
 450

<210> 5

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Amino acid
 sequence for light chain of recombinant antibody

<400> 5

Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
 1 5 10 15

Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Ser Ser
 20 25 30

Tyr Leu His Trp Tyr Arg Gln Lys Ser Gly Ala Ser Pro Lys Leu Trp
 35 40 45

Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
 50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu
 65 70 75 80

Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Gly Tyr Arg
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala
 100 105 110

Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly
 115 120 125

Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Arg Asp Ile
 130 135 140

Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu
 145 150 155 160

Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser
 165 170 175

Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr
 180 185 190

Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser
 195 200 205

Phe Asn Arg Asn Glu Cys
 210

<210> 6

<211> 462

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Amino acid
 sequence for heavy chain of recombinant antibody
 with C-terminal histidine tag sequence

<400> 6

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Met Ile Ser Cys Arg Thr Ser Ala Tyr Thr Phe Thr Glu Asn
 20 25 30

Thr Val His Trp Val Lys Gln Ser His Gly Glu Ser Leu Glu Trp Ile
 35 40 45

Gly Gly Ile Asn Pro Tyr Tyr Gly Gly Ser Ile Phe Ser Pro Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Arg Ala Gly Ala Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro
 115 120 125
 Leu Ala Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly
 130 135 140
 Cys Leu Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn
 145 150 155 160
 Ser Gly Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln
 165 170 175
 Ser Gly Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr
 180 185 190
 Trp Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser
 195 200 205
 Thr Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile
 210 215 220
 Asn Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn
 225 230 235 240
 Leu Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp
 245 250 255
 Val Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp
 260 265 270
 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn
 275 280 285
 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn
 290 295 300
 Ser Thr Ile Arg Val Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp
 305 310 315 320

Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro
 325 330 335

Ser Pro Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala
 340 345 350

Pro Gln Val Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys
 355 360 365

Asp Val Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile
 370 375 380

Ser Val Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp
 385 390 395 400

Thr Ala Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys
 405 410 415

Leu Asn Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys
 420 425 430

Asn Val Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile
 435 440 445

Ser Arg Ser Pro Gly Lys Gly Gly His His His His His His
 450 455 460

<210> 7

<211> 80

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HC 5' coding
 strand primer RAPHC-5

<400> 7

gccaccatgg aatggagttg gatattttctc tttctcctgt caggaactgc aggtgtccac 60
 tctgaggtcc agctgcarca 80

<210> 8

<211> 80

<212> DNA

<213> Artificial Sequence

<400> 8

gccaccatgg attttctggt gcagattttc agcttcttgc taatcagtgc ctcagttgca 60
atgtccagag gagaaaatgt 80

<210> 9
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:HC 3'
non-coding strand primer

<400> 9
ctaagctcat ttacccggag accg 24

<210> 10
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LC 3'
non-coding strand primer

<400> 10
ctcaggacct ttgtctctaa cactc 25

<210> 11
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:HC His 5'
coding strand primer

<400> 11
ctcccgggtct ccgggtaaag gtggccatca ccaccatcac cattgagctt agaagggcaa 60
tt 62

<210> 12
<211> 62
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:HC His 5'
non-coding strand primer

<400> 12

aattgccctt ctaagctcaa tggatgatggg ggtgatggcc acctttaccc ggagaccggg 60
ag 62

001050"000100